About us

Pioneering the Future of Immunotherapy

At TJ Bio, we are committed to creating innovative immunotherapies for patients worldwide. As a fully integrated biotech company, we strive to lead the way in autoimmune diseases and immuno-oncology, bringing life-changing therapies from lab to patient. Our approach creates a diverse and sustainable revenue model , generating value for the Company and our shareholders in China and globally.

Formed through strategic restructuring in early 2024, TJ Bio builds upon established R&D capabilities in Shanghai and Being (since 2016) and manufacturing facilities in Hangzhou (since 2020). This integration has strengthened our capacity to advance our differentiated pipeline, including three near-BLA assets.
Our discovery and research engine drives a next-generation pipeline of highly innovative clinical and pre-clinical assets, focusing on bi-specific antibodies and antibody-drug conjugate for autoimmune diseases and oncology.
We operate under two key principles:
  • In China for China: Delivering innovative medicines at controlled manufacturing costs to the local market.
  • In China for Global: Partnering with global companies to develop select assets for worldwide markets.

Fully Integrated Value Chain: From Lab to Patients

Discovery Engine

TJ Bio’s discovery team combines cutting-edge science with extraordinary passion to drive innovation. Our proprietary technology platforms have yielded a robust pipeline of assets with First-in-Class or Best-in-Class potential.

Our innovative pipeline spans three generations of development. The first wave consists of monoclonal antibodies and fusion proteins, primarily in Phase 2/3 or near-BLA stages. Our second wave focuses on bi-specific antibodies for cancers, currently at IND-ready or early clinical development stages. Most recently, we've embarked on our third wave of innovation, concentrating on bi-specific antibodies and antibody-drug conjugates, mainly targeting autoimmune diseases.

Our Pipeline

Advanced and Differentiated Clinical Pipeline

Oncology
Immunology
Metabolic
AssetsTarget/MoAAreasIndicationsPhase 1Phase 2Phase 3BLAPartnershipRights
Eftansomatropin alfaLong-acting hGH
PGHD
Submitted
China
FelzartamabCD38
MM, lgAN, AMR, PMN
Submitted
Greater China
Efmedaglutide alfaLong-acting GLP-1
Obesity, Diabetes
2025
China1
LemzoparlimabCD47
MDS, AML
Greater China
UliledlimabCD73
NSCLC
Greater China2
PlonmarlimabGM-CSF
MAS, sHLH, GA
Global
GivastomigClaudin18.2 x 4-1BB
Gastric cancer
Greater China
Efineptakin alfaIL-7
TNBC, CAR-T
Greater China
TJ-L1A3PD-L1 x LAG3
Solid tumors
Greater China
IzastobartC5aR
AAV
Greater China, S. Korea
PGHD: Pediatric growth hormone deficiency; MM: Multiple Myeloma; IgAN: IgA Nephrology; AMR: Antibody-Mediated Rejection; PMN: Primary Membranous Nephropathy; MDS: Myelodysplastic Syndrome; AML: Acute Myeloid Leukemia; NSCLC: Non-small Cell Lung Cancer; MAS: Macrophage Activation Syndrome; sHLH: Secondary Hemophagocytic lymphohistiocytosis; GA: Gouty Arthritis; TNBC: Triple Negative Breast Cancer; AAV: ANCA-Associated Vasculitis
1.Efmedaglutide alfa (TJ103/TG103) is currently undergoing Phase 3 clinical trials sponsored by CSPC. For information regarding BLA plans, please refer to CSPC's official disclosures.
2.TJ Bio and Sanofi have entered into strategic partnership for uliledlimab in Greater China: https://tjbio.com/news/11854

News Center

Learn more
Learn more